Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 234-253 http://medscipublisher.com/index.php/cge 249 Guerrouahen B.S., Maccalli C., Cugno C., Rutella ., and Akporiaye E.T., 2019, Reverting immune suppression to enhance cancer immunotherapy, Frontiers in Oncology, 9: 1554. https://doi.org/10.3389/fonc.2019.01554 Hanoteau A., Newton J.M., Krupar R., Huang C., Liu H.C., Gaspero A., Gartrell R.D., Saenger Y.M., Hart T.D., Santegoets S.J., Laoui D., Spanos C., Parikh F., Jayaraman P., Zhang B., Van der Burg S.H., Van Ginderachter J.A., Melief C.J.M., and Sikora A.G., 2019, Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy, Journal for Immunotherapy of Cancer, 7(1): 10. https://doi.org/10.1186/s40425-018-0485-9 PMID: 30646957 PMCID: PMC6332704 Hou W.T., Yi C., and Zhu H., 2022, Predictive biomarkers of colon cancer immunotherapy: present and future, Frontiers in Immunology, 13: 1032314. https://doi.org/10.3389/fimmu.2022.1032314 Huang C.L., Wang X.F, Wang Y.Z., Feng Y.Y., Wang X.M., Chen S., Yan P.D., Liao J., Zhang Q., Mao C.Z., Li Y., Wang L.X., Wang X.Y., Yi W., Cai W.B., Chen S.D., Hong N., He W.L., Chen J., and Jin W.F., 2024a, Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47, Nature Cancer, 5(3): 500-516. https://doi.org/10.1038/s43018-023-00691-z Huang T.X., Huang H.S., Dong S.W., Chen J.Y., Zhang B., Li H.H., Zhang T.T., Xie Q., Long Q.Y., Yang Y., Huang L.Y., Zhao P., Bi J., Lu X.F., Pan F., Zou C., and Fu L., 2024b, ATP6V0A1-dependent cholesterol absorption in colorectal cancer cells triggers immunosuppressive signaling to inactivate memory CD8(+) T cells, Nature Communications, 15(1): 5680. https://doi.org/10.1038/s41467-024-50077-7 Jia W.Q., Shen X.N.., Guo ZC.., Cheng X., and Zhao R., 2024, The future of cancer vaccines against colorectal cancer, Expert opinion on Biological Therapy, 24(4): 269-284. https://doi.org/10.1080/14712598.2024.2341744 Jiang S.S., Xie Y.L., Xiao X.Y., Kang Z.R., Lin X.L., Zhang L., Li C.S., Qian Y., Xu P.P., Leng X.X., Wang L.W., Tu S.P., Zhong M., Zhao G., Chen J.X., Wang Z., Liu Q., Hong J., Chen H.Y., Chen Y.X., and Fang J.Y., 2023, Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer, Cell Host & Microbe., 31(5): 781-797. https://doi.org/10.1016/j.chom.2023.04.010 Jin K.T., Chen B., Liu Y.Y., Lan H.U., and Yan J.P., 2021, Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer, Cancer Cell International, 21: 83. https://doi.org/10.1186/s12935-021-01763-9 Kang J.H., and Zappasodi R., 2023, Modulating treg stability to improve cancer immunotherapy, Trends in Cancer, 9(11): 911-927. https://doi.org/10.1016/j.trecan.2023.07.015 Karlsson S., and Nyström H., 2022, The extracellular matrix in colorectal cancer and its metastatic settling-alterations and biological implications, Critical Reviews in Oncology/Hematology, 175: 103712. https://doi.org/10.1016/j.critrevonc.2022.103712 Kawai T., Nyuya A., Mori Y., Tanaka T., Tanioka H., Yasui K., Toshima T., Taniguchi F., Shigeyasu K., Umeda Y., Fujiwara T., Okawaki M.,, Yamaguchi Y., Goel A., and Nagasaka T., 2021, Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations, Clinical Epigenetics, 13(1): 117. https://doi.org/10.1186/s13148-021-01104-7 Kim C.G., Sang Y.B., Lee J.H., and Chon H.J., 2021, Combining cancer vaccines with immunotherapy: establishing a new immunological approach, International Journal of Molecular Sciences, 22(15): 8035. https://doi.org/10.3390/ijms22158035 Kroemer G., and Zitvogel L., 2021, Immune checkpoint inhibitors, The Journal of Experimental, Medicine, 218(3): e20201979. https://doi.org/10.1084/jem.20201979 Kuai R., Yuan W., Son S., Nam J., Xu Y., Fan Y., Schwendeman A., and Moon J.J., 2018, Elimination of established tumors with nanodisc-based combination chemoimmunotherapy, Science Advances, 4(4): eaao1736. https://doi.org/10.1126/sciadv.aao1736 Lazarus J., Maj T., Smith J.J., Perusina Lanfranca M., Rao A., D'Angelica M.I., Delrosario L., Girgis A., Schukow C., Shia J., Kryczek I., Shi J.Q., Wasserman I., Crawford H., Nathan H., Di Magliano M.P., Zou W.P., and Frankel T.L., 2018, Spatial and phenotypic immune profiling of metastatic colon cancer, JCI insight, 3(22): e121932. https://doi.org/10.1172/jci.insight.121932 Lee Y.S., Lee W.S., Kim C.W., Lee S.J., Yang H., Kong S.J., Ning J., Yang K.M., Kang B., Kim W.R., Chon H.J., and Kim C., 2020, Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer, Journal for Immunotherapy of Cancer, 8(2): e000857. https://doi.org/10.1136/jitc-2020-000857 Lenz H.J., Parikh A., Spigel D.R., Cohn A.L., Yoshino T., Kochenderfer M., Elez E., Shao S.H., Deming D., Holdridge R., Larson T., Chen E., Mahipal A., Ucar A., Cullen D., Baskin-Bey E., Kang T., Hammell A.B., Yao J., and Tabernero J., 2024, Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial, Journal for Immunotherapy of Cancer, 12(3): e008409. https://doi.org/10.1136/jitc-2023-008409
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==